Novo Nordisk A/S: Novo Nordisk receives positive opinion on Xultophy(r) (IDegLira) from the European regulatory authorities

Bagsvaerd, Denmark, Jul 25, 2014 (GLOBE NEWSWIRE via COMTEX) --
 
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion, recommending marketing authorisation for Xultophy® for the treatment of type 2 diabetes mellitus in adults.
 
Xultophy® is the intended brand name for IDegLira, the first once-daily single injection combination of Tresiba® (insulin degludec) and Victoza® (liraglutide), developed for the treatment of type 2 diabetes. The CHMP positive opinion recommends that Xultophy® will be indicated for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.
 
For further information
 
Media:  
Lars Pallisgaard +45 3079 3730 [email protected]
Ken Inchausti (US) +1 609 514 8316 [email protected]
Investors:  
Kasper Roseeuw Poulsen +45 3079 4303 [email protected]
Jannick Lindegaard Denholt +45 3079 8519 [email protected]
Daniel Bohsen +45 3079 6376 [email protected]
Frank Daniel Mersebach (US) +1 609 235 8567 [email protected]
Company announcement No 45 / 2014
 
Company Announcement No 45 2014 http://hugin.info/2013/R/1837250/638603.pdf
 
HUG#1837250
 
Copyright (C) 2014 GlobeNewswire, Inc. All rights reserved.

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.